413 related articles for article (PubMed ID: 26894890)
1. IGF-1 protects dopamine neurons against oxidative stress: association with changes in phosphokinases.
Ayadi AE; Zigmond MJ; Smith AD
Exp Brain Res; 2016 Jul; 234(7):1863-1873. PubMed ID: 26894890
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
4. Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions.
Quesada A; Micevych PE
J Neurosci Res; 2004 Jan; 75(1):107-16. PubMed ID: 14689453
[TBL] [Abstract][Full Text] [Related]
5. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
6. Human Basic Fibroblast Growth Factor Inhibits Tau Phosphorylation via the PI3K/Akt-GSK3β Signaling Pathway in a 6-Hydroxydopamine-Induced Model of Parkinson's Disease.
Yang PH; Zhu JX; Huang YD; Zhang XY; Lei P; Bush AI; Xiang Q; Su ZJ; Zhang QH
Neurodegener Dis; 2016; 16(5-6):357-69. PubMed ID: 27228974
[TBL] [Abstract][Full Text] [Related]
7. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
[TBL] [Abstract][Full Text] [Related]
8. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages.
Aoi M; Date I; Tomita S; Ohmoto T
Neurosci Res; 2000 Apr; 36(4):319-25. PubMed ID: 10771110
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
10. Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease.
Datla KP; Christidou M; Widmer WW; Rooprai HK; Dexter DT
Neuroreport; 2001 Dec; 12(17):3871-5. PubMed ID: 11726811
[TBL] [Abstract][Full Text] [Related]
11. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
Jalewa J; Sharma MK; Gengler S; Hölscher C
Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
[TBL] [Abstract][Full Text] [Related]
12. Intranasal Administration of GDNF Protects Against Neural Apoptosis in a Rat Model of Parkinson's Disease Through PI3K/Akt/GSK3β Pathway.
Yue P; Gao L; Wang X; Ding X; Teng J
Neurochem Res; 2017 May; 42(5):1366-1374. PubMed ID: 28247332
[TBL] [Abstract][Full Text] [Related]
13. Tetramethylpyrazine Analogue CXC195 Protects Against Dopaminergic Neuronal Apoptosis via Activation of PI3K/Akt/GSK3β Signaling Pathway in 6-OHDA-Induced Parkinson's Disease Mice.
Chen L; Cheng L; Wei X; Yuan Z; Wu Y; Wang S; Ren Z; Liu X; Liu H
Neurochem Res; 2017 Apr; 42(4):1141-1150. PubMed ID: 28005221
[TBL] [Abstract][Full Text] [Related]
14. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
Datla KP; Blunt SB; Dexter DT
Mov Disord; 2001 May; 16(3):424-34. PubMed ID: 11391735
[TBL] [Abstract][Full Text] [Related]
15. The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling.
Baluchnejadmojarad T; Eftekhari SM; Jamali-Raeufy N; Haghani S; Zeinali H; Roghani M
Exp Gerontol; 2017 Dec; 100():70-76. PubMed ID: 29107062
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner.
Boshoff EL; Fletcher EJR; Duty S
Neuropharmacology; 2018 Jul; 137():156-163. PubMed ID: 29698669
[TBL] [Abstract][Full Text] [Related]
17. ALCAR Exerts Neuroprotective and Pro-Neurogenic Effects by Inhibition of Glial Activation and Oxidative Stress via Activation of the Wnt/β-Catenin Signaling in Parkinsonian Rats.
Singh S; Mishra A; Shukla S
Mol Neurobiol; 2016 Sep; 53(7):4286-301. PubMed ID: 26223802
[TBL] [Abstract][Full Text] [Related]
18. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
19. Nasal application of kisspeptin-54 mitigates motor deficits by reducing nigrostriatal dopamine loss in hemiparkinsonian rats.
Sinen O; Sinen AG; Derin N; Aslan MA
Behav Brain Res; 2024 Jun; 468():115035. PubMed ID: 38703793
[TBL] [Abstract][Full Text] [Related]
20. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
